Status:
TERMINATED
Apremilast in the Treatment of Uveitis
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
Celgene Corporation
Conditions:
Uveitis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to assess the safety and efficacy of Apremilast in the treatment of uveitis.
Eligibility Criteria
Inclusion
- patients with vision-threatening autoimmune uveitis
- failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects
Exclusion
- serious concomitant illness that could interfere with the subject's participation
- previous or current use of an alkylating agent
- use of CYP3A4 inhibitors during the trial
- TNF blocker use within the 8 weeks prior to enrollment
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00889421
Start Date
November 1 2009
End Date
June 1 2011
Last Update
July 8 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239